SAB Biotherapeutics Q1 2024 GAAP EPS $(0.43) Beats $(0.96) Estimate
SAB Biotherapeutics Q1 2024 GAAP EPS $(0.43) Beats $(0.96) Estimate
SAB Biotherapeutics 2024年第一季度GAAP每股收益美元(0.43美元)超过预期(0.96美元)
SAB Biotherapeutics (NASDAQ:SABS) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.96) by 55.21 percent. This is a 186.67 percent decrease over losses of $(0.15) per share from the same period last year.
SAB Biotherapeutics(纳斯达克股票代码:SABS)公布的季度亏损为每股0.43美元,比分析师普遍预期的0.96美元(0.96美元)高出55.21%。这比去年同期每股亏损0.15美元(0.15美元)下降了186.67%。
SAB reaffirms it has sufficient cash, assuming the receipt of funds upon the exercise of all outstanding Tranche B warrants, that is expected to be sufficient to fund its operations into 2026.
SAB重申,假设在行使所有未偿还的B批认股权证后获得资金,则有足够的现金,预计足以为其2026年的运营提供资金。